Home: Maucher Jenkins

Intellectual Property

Patents | Trade Marks | Designs

新闻与事件

新闻活动

Actavis v ICOS: Obvious-to-Try a Dose of Clarity

日期: 17 May 2019

EmailTwitterLinkedInXingWeChat

 

The Supreme Court of England and Wales on 27 March 2019 handed down judgment in the case of Actavis Group PTC EHF v ICOS Corp on appeal from the Court of Appeal. Finding in favour of the respondents, Acatvis, TEVA and Mylan, the court upheld the Court of Appeal’s decision that a dosage patent for tadalafil in the treatment of male erectile dysfunction was invalid for lack of inventive step. The methodology employed by the Supreme Court to the question of inventive step affirms the current practice of the UK courts and the jurisprudence of the EPO. In the court’s view, it was clear that a skilled team was engaged in the familiar and routine testing of a drug to establish the appropriate dosage regimen in order to implement the teaching of the prior art. It was obvious to embark on that exercise and carry out tests in a routine way until the appropriate dose was ascertained, and such tests included the completion of dose-ranging studies routinely carried out in Phase IIb of clinical trials.

 

Our comment in (2019) 41 EIPR, Issue 7 considers the judgment and its implications.

 

C
本网站使用cookies。

其中一些cookies是必要的,而另一些cookies则通过分析网站的使用方式来帮助我们改善您的用户体验。有关我们使用的cookies的更多详细信息,请查看我们的隐私政策

必要的Cookies

必要的cookies可实现网站核心功能。 没有这些cookies,网站将无法正常运行。这些cookies只能通过更改浏览器选项来禁用。

分析性Cookies

分析性cookies通过收集和报告使用信息帮助我们改进网站。

x